{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:48Z","timestamp":1782337308639,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.06.018","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:07:56Z","timestamp":1750680476000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients With B-Cell Non-Hodgkin Lymphoma in the United States"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-7551","authenticated-orcid":false,"given":"Mohammed","family":"Zuber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-4418","authenticated-orcid":false,"given":"Shaimaa","family":"Elshafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-7644","authenticated-orcid":false,"given":"Shifa","family":"Taj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-4595","authenticated-orcid":false,"given":"Lorenzo","family":"Villa Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jtct.2025.06.018_bib0001","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-Cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.018_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.jtct.2025.06.018_bib0003","doi-asserted-by":"crossref","unstructured":"Chen Y-J, Abila B, Mostafa Kamel Y. CAR-T: What Is Next? 2023;15(3):663.","DOI":"10.3390\/cancers15030663"},{"key":"10.1016\/j.jtct.2025.06.018_bib0004","series-title":"AUCATZYL (obecabtagene autoleucel) [package insert]","year":"2024"},{"issue":"10254","key":"10.1016\/j.jtct.2025.06.018_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.018_bib0006","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large b cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.018_bib0007","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. 2017;377(26):2531-2544. doi:10.1056\/NEJMoa1707447","DOI":"10.1056\/NEJMoa1707447"},{"key":"10.1016\/j.jtct.2025.06.018_bib0008","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. 2019;380(1):45-56. doi:10.1056\/NEJMoa1804980","DOI":"10.1056\/NEJMoa1804980"},{"issue":"16","key":"10.1016\/j.jtct.2025.06.018_bib0009","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.018_bib0010","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2025.06.018_bib0011","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.018_bib0012","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.018_bib0013","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.018_bib0014","series-title":"Chimeric antigen receptor T-cell therapy real-world assessment of total cost of care and clinical events for the treatment of relapsed or refractory lymphoma","author":"Sahli","year":"2021"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.018_bib0015","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae059","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectrum"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.018_bib0017","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLOS Medicine"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.018_bib0018","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1007\/s12325-022-02087-4","article-title":"Real-world treatment patterns after CD19-directed CAR T cell therapy among patients with diffuse large B cell lymphoma","volume":"39","author":"Jalbert","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2025.06.018_bib0019","doi-asserted-by":"crossref","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ, et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium. 2024;42(30):3581-3592. doi:10.1200\/jco.23.02786","DOI":"10.1200\/JCO.23.02786"},{"issue":"24","key":"10.1016\/j.jtct.2025.06.018_bib0020","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.018_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.018_bib0022","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.018_bib0023","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/bloodadvances.2022009025","article-title":"Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy","volume":"7","author":"Furqan","year":"2023","journal-title":"Blood advances"},{"key":"10.1016\/j.jtct.2025.06.018_bib0024","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) \u2013 B-Cell lymphomas. Version [Version 2.2025]. Accessed Mar 1, 2025."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:39:13Z","timestamp":1752619153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"alternative-id":["S2666636725012618"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients With B-Cell Non-Hodgkin Lymphoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}